Centers | ||
|
|
|
FDA Oncology Center of Excellence Project Catalyst | test | Edinburgh Drug Discovery |
Providing a regulatory platform to connect scientific knowledge, creative insight, and medical professionals to foster early-stage product innovation |
sfgd |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
Partnerships |
Events |
Jobs |
Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all The Division of Signal Transduction TherapyA vital asset of the MRC-PPU is the Division of Signal Transduction Therapy (DSTT) which was established in 1998. This division operates as a unique collaboration between scientists in the MRC-PPU (all PIs including Ronald Hay FRS Honorary PI of... View all Evotec and Yale University form Open Innovation AllianceEvotec and Yale intend to leverage first rate science performed at Yale University together with Evotec's drug discovery infrastructure and expertise into highly innovative discovery approaches in diseases of high unmet medical need. Initially,... View all |
No EVENTS for listing |
No Job Posts |
